1.
Klin Med (Mosk)
; 91(7): 55-60, 2013.
Artigo
em Russo
| MEDLINE
| ID: mdl-24437172
RESUMO
We compared the efficacy of recombinant infliximab and adalimumab in patients with severe and moderately severe rheumatoid arthritis. Infliximab produced rapid anti-inflammatory effect in the early period of therapy whereas adalimumab ensured more stable reduction of clinical and laboratory parameters of activity.